RxDoctor Payments DataLook up a doctor →

Michelle Giddings, APRN

Psychiatric/Mental Health · Las Vegas, NVNPI 1336303072

Payments from drug & device makers

$131,303in general payments, 2019–2025

Across 933 payments — averaging $140.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$49K
  • E.r. Squibb & Sons, L.L.C.$42K
  • Axsome Therapeutics, Inc.$28K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • AbbVie$2K
  • Supernus Pharmaceuticals, Inc.$1K
  • plus $7K from 24 others

What the payments were for

  • Consulting fees$24,76819%
  • Speaking & faculty fees$70,97454%
  • Travel & lodging$15,80612%
  • Food & beverage$19,57715%
  • Education$1790%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$131,303 in reported general payments places this provider in the 95th percentile of 362 psychiatric/mental health providers in Nevada.

See all psychiatric/mental health providers in Nevada

Medicare billing

Part B allowed, 2024
$110,242
Medicare patients
186
Services billed
1,233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$92,904
RexultiBrexpiprazole21$32,390
LatudaLurasidone Hcl12$16,407
SeroquelQuetiapine Fumarate14$8,214
DayvigoLemborexant20$6,592
Adderall XrDextroamphetamine/Amphetamine15$5,771
Quetiapine Fumarate255$5,555
Chlorpromazine Hcl23$5,081
BelsomraSuvorexant12$5,080
Risperidone268$4,480
Desvenlafaxine Succinate ErDesvenlafaxine Succinate25$3,471
Hydroxyzine Hcl207$3,246
Oxcarbazepine58$3,140
Carbamazepine ErCarbamazepine20$2,864
Topiramate178$2,782

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$1,050$92,90411 claims
Otsuka America Pharmaceutical, Inc.Rexulti$49,163$32,39021 claims
Sunovion Pharmaceuticals Inc.Latuda$349$16,40712 claims
Eisai Inc.Dayvigo$113$6,59220 claims
MerckBelsomra$40$5,08012 claims
Almatica Pharma LLCSertraline Hcl$249$1,700147 claims
Teva Pharmaceuticals USA, Inc.Loxapine$865$1,55130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 362 psychiatric/mental health providers in Nevada.

Other psychiatric/mental health in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →